Pulmonary hypertension in systemic lupus erythematosus: Echocardiography-based definitions predict 6-year survival

Rheumatology (United Kingdom)

Volumn 53, Issue 7, 2014, Pages 1256-1263

  Hübbe Tena, Claudia ^a   Gallegos Nava, Selma ^a   Márquez Velasco, Ricardo ^a   Castillo Martínez, Diana ^a   Vargas Barrón, Jesus ^a   Sandoval, Julio ^a   Amezcua Guerra, Luis M ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Echocardiography; Endothelin 1; MCP 1; Pulmonary hypertension; Survival; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; ENDOTHELIN 1; GAMMA INTERFERON; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTHRITIS; ARTICLE; BLEEDING; CARDIOVASCULAR PARAMETERS; DISEASE DURATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT ATRIUM DIAMETER; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; INTERVENTRICULAR SEPTAL THICKNESS; LONG TERM SURVIVAL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; ORGAN DAMAGE; ORGAN INJURY; POST HOC ANALYSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULITIS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE;

ECHOCARDIOGRAPHY; ENDOTHELIN-1; MCP-1; PULMONARY HYPERTENSION; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; COHORT STUDIES; COMORBIDITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY EMBOLISM; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; VASCULITIS;

EID: 84902969271     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu012     Document Type: Article

References (33)

1. Galiè N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-537.
2. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl):S43-54.
3. Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 2009; 30:429-39.
4. Amezcua-Guerra LM. Pulmonary hypertension associated with systemic lupus erythematosus. Salud Cienc 2012; 18:746-50.
5. Foïs E, Le Guern V, Dupuy A et al. Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients. Clin Exp Rheumatol 2010; 28:836-41.
6. Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013; 12:410-5.
7. Johnson SR, Gladman DD, Urowitz MB, Ibañez D, Granton JT. Pulmonary hypertension in systemic lupus. Lupus 2004; 13:506-9.
8. Prabu A, Patel K, Yee CS et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology 2009; 48:1506-11.
9. Quismorio FP Jr, Sharma O, Koss M et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13:349-59.
10. Winslow TM, Ossipov MA, Fazio GP et al. Five-year followup study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995; 129:510-5.
11. Johnson SR, Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011; 20:277-86.
12. Chung SM, Lee CK, Lee EY et al. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006; 25:866-72.
13. Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012; 2012:854941.
14. Hoeper MM, Lee SH, Voswinckel R et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48:2546-52.
15. Amezcua-Guerra LM, Springall R, Arrieta-Alvarado AA et al. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus. Clin Lab 2011; 57:607-13.
16. Han B, Bojalil R, Amezcua-Guerra LM et al. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Int Immunol 2008; 20:1067-75.
17. Castillo-Martínez D, Amezcua-Guerra LM, Bojalil R. Neutropenia and the risk of infections in ambulatory patients with systemic lupus erythematosus: a three-year prospective study cohort. Lupus 2011; 20:998-1000.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
19. Gladman DD, Ibáñez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288-91.
20. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363-9.
21. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-90.
22. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
23. Fisher MR, Forfia PR, Chamera E et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179:615-21.
24. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17:1292-8.
25. Burdt MA, Hoffman RW, Deutscher SL et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42:899-909.
26. Chow SL, Chandran V, Fazelzad R, Johnson SR. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus 2012; 21:353-64.
27. Pope J. An update in pulmonary hypertension in systemic lupus erythematosus-do we need to know about it? Lupus 2008;17:274-7.
28. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8:42-54.
29. de Souza AW, Silva NP, de Carvalho JF et al. Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndrome. Lupus 2007; 16:782-7.
30. Matsuda J, Tsukamoto M, Gohchi K et al. Effect of totalbody cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 1992; 88:189-93.
31. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5:200-6.
32. Itoh T, Nagaya N, Ishibashi-Ueda H et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006; 11:158-63.
33. Gourh P, Arnett FC, Assassi S et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009;11:R147.